Key Metrics
0.91
5-Year SI
5-year SI
- N/A 2-year SI
- 0.9 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Clinical significance
- Hematologic disorders
- Gene expression
- Cytotoxic Therapy
- Clonal hematopoiesis
- Chimeric antigen receptor
- Machine learning
- Bispecific antibody
- Minimal residual disease
- CpG island hypermethylation
- Bortezomib
- Tumor burden
- Hematopoietic stem cell
- Artificial intelligence
- Diffuse large B-cell lymphoma
- Monoclonal B-cell lymphocytosis
- Hyperthermia
- Disease progression
- Health equity
Journal Specifications
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2020 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in BLOOD CANCER DISCOVERY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma.
- 24 Feb 25
- Blood cancer discovery
-
Full paper
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma.
- 10 Feb 25
- Blood cancer discovery
-
Full paper
SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity.
- 10 Feb 25
- Blood cancer discovery
-
Full paper
High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study.
- 6 Feb 25
- Blood cancer discovery
-
Full paper
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
- 6 Feb 25
- Blood cancer discovery
-
Full paper
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.
- 3 Feb 25
- Blood cancer discovery
Scite analysis
Powered by scite_
499 articles received 3.4k citations see all
- 206 Supporting
- 3,183 Mentioning
- 21 Contrasting
Editorial notices
- 2 Retractions
- 0 Withdrawals
- 4 Corrections
- 1 Errata
- 0 Expression of Concern
FAQs
How long has BLOOD CANCER DISCOVERY been actively publishing?
BLOOD CANCER DISCOVERY has been in operation since 2020 till date.
What is the publishing frequency of BLOOD CANCER DISCOVERY ?
BLOOD CANCER DISCOVERY published with a Bi-monthly frequency.
How many articles did BLOOD CANCER DISCOVERY publish last years ?
In 2024, BLOOD CANCER DISCOVERY published 121 articles.
What is the eISSN & pISSN for BLOOD CANCER DISCOVERY ?
For BLOOD CANCER DISCOVERY,eISSN is 2643-3249 and pISSN is2643-3230.
Who is the publisher of BLOOD CANCER DISCOVERY ?
AMER ASSOC CANCER RESEARCH is the publisher of BLOOD CANCER DISCOVERY.